PopVax Unveils RNA Foundry for Personalized Cancer Vaccines
Hyderabad-based PopVax launches a facility aimed at creating custom cancer vaccines tailored to individual patients.
PopVax has launched RNA Foundry to produce personalized cancer vaccines.
The facility adheres to global Good Manufacturing Practices and utilizes advanced mRNA technology.
The company aims to manufacture over 100 personalized vaccines in the next year.
On October 30, 2026, PopVax, a biotech startup based in Hyderabad, announced the launch of its RNA Foundry, a cutting-edge facility dedicated to the research, development, and production of personalized cancer vaccines. Founded in 2021, PopVax aims to revolutionize cancer treatment by tailoring vaccines to the unique biological and genetic profiles of individual patients. Founder Soham Sankaran emphasized the challenges of producing high-quality mRNA medicines, stating that the traditional approach of large pharmaceutical companies often fails to address the specific needs of patients.
The RNA Foundry is equipped with proprietary mRNA technology and a stable lipid nanoparticle formulation, ensuring compliance with global Good Manufacturing Practices. Unlike conventional vaccines that use weakened or inactivated viruses, mRNA vaccines instruct the body’s cells to produce a harmless viral protein, thereby training the immune system to recognize and combat cancer cells effectively. Sankaran noted that the facility is not only designed for PopVax's own vaccine candidates but is also open to developing personalized solutions for patients across the country.
In a bold commitment, PopVax plans to manufacture more than 100 personalized cancer vaccines within the next year. The company is encouraging individuals to reach out with their cancer type and sequencing information, allowing for tailored vaccine development on a case-by-case basis. This initiative represents a significant step towards making advanced cancer treatments more accessible to those in need.
The announcement has garnered positive reactions on social media, with users expressing excitement about the potential impact of personalized cancer vaccines. Many highlighted the importance of deep tech innovation in India, with comments reflecting optimism about the future of research and development in the country. One user remarked on the significance of the development, stating that it could change the landscape of cancer treatment for many individuals.
Looking ahead, PopVax's RNA Foundry is poised to play a crucial role in the evolution of cancer care in India. As the company embarks on this ambitious journey, it aims to set a precedent for personalized medicine, potentially transforming the way cancer is treated and managed. The next steps will involve the initial production of vaccines and outreach to patients, marking a new chapter in the fight against cancer.
